A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats.

Ira M LonginiYang YangThomas R FlemingCésar Muñoz-FontelaRui WangSusan S EllenbergGeorge QianM Elizabeth HalloranMartha NasonVictor De GruttolaSabue MulanguYunda HuangChristl A DonnellyAna-Maria Henao Restrepo

Published in: Clinical trials (London, England) (2022)

This event-driven design takes into the account the potentially sporadic spread of Marburg virus. The proposed trial design may be applicable for other pathogens against which effective vaccines are not yet available.

Keyphrases

infectious diseases
study protocol
phase iii
clinical trial
phase ii
late onset
randomized controlled trial
high throughput
gram negative
open label
multidrug resistant
antimicrobial resistance
early onset